How Bout that!- Monkeypox cases are rising rapidly across the U.S., and while the federal government is poised to declare the outbreak a public health emergency, cases globally are putting pressure on supplies of potential vaccines and treatments. Tecovirimat, known by its brand TPOXX, is the only available treatment — though it has only been tested for use against smallpox, a related virus. TPOXX maker SIGA Technologies (SIGA) is now fielding a surge of requests from countries looking for supply. In the past two years, the company has produced and delivered 360,000 courses — each of which entails 2 pills a day for 14 days — for the U.S. to replenish the stockpile, which now has just under 2 million courses. Aside from the U.S., Canada was the only other country that was stockpiling courses, according to SIGA CEO Phil Gomez. Monkeypox Virus. 3D Render "We do have a lot of inquiries coming in from dozens of countries that are now trying to catch up and establish stockpiles," he told Yahoo Finance on Friday. The company has a total of $56 million in new orders of treatment courses this year, from a half dozen countries and entities, and anticipates about half of the orders to be delivered by September. "We're certainly working with our network to expand manufacturing, but we were anticipating a large number of orders over the next few years, so we have product available and in our supply chain to advance in response to these orders," Gomez said. Public health emergency The World Health Organization (WHO) has already announced a public health emergency globally, as more countries continue to report cases and deaths. There are now more than 16,000 cases in 75 countries. But vaccines, treatments and even testing continue to be limited in availability both abroad and in the U.S., despite federal governments' efforts and reassurances about available tools. In African countries, where the disease has been endemic for some time, vaccines are not available. Despite the stockpile, TPOXX remains elusive as the burden of the regulatory process deters or confuses providers. The FDA and CDC have asked that paperwork be done to collect safety data on the use of the pill, since it is not approved for monkeypox. TPOXX is available both intravenously and as a pill and was approved by the FDA for use against smallpox in 2018, after which the U.S. government began to stockpile doses. The National Institutes of Allergy and Infectious Diseases (NIAID) is looking to begin clinical trials for monkeypox in coming months, Gomez said. Monkeypox is largely transmitted through close physical contact with skin or mucus and saliva. It is not considered a sexually transmitted disease, but is largely circulating among men who have sex with men, prompting the WHO to caution the community to reduce the number of partners for now to help curb the spread. The first case in a pregnant woman was recently reported in the U.S. Health care providers who do not regularly treat LGBTQ+ patients are struggling to identify cases, often testing for other STDs first, which could lead to missed diagnoses that aren't already symptomatic. Symptoms include fever, muscle aches, chills and skin lesions. A positive case requires weeks-long isolation — much longer than COVID-19. The virus has been endemic in parts of Africa, and two specific strains, known as clades, are circulating there. The West African clade, which is in circulation globally, has a low mortality rate, while the Congo Basin clade has a higher mortality rate. But countries like Brazil and Spain have reported deaths, spurring concern about the ability to contain the disease globally. "Unfortunately, I think the original perception that this was going to be a self-limiting infection with not a lot of morbidity and mortality just hasn't played out," Gomez said, saying the response continues to be slow. As with COVID-19, concerns about access to life-saving drugs and vaccines globally and equitably have grown. SIGA has already donated treatment courses in Africa, and is in discussions with the WHO and global non-profits to ensure equitable availability, Gomez said.
Check this out. After I called the apparent bottom to the day on June 16 "The Immaculate Post" then I call this particular spurt again to the day- Wed a week before it happened... now after 13% of unmitigated joy.. Now... Jim Cramer Says Now Is the Time to Pull the Trigger on Stocks Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, reminds us the ‘conventional wisdom’ at a time like this is to dump stocks. But Cramer points out that Fed Chair Powell has indicated that the central bank will likely slow up its pace of interest rate hikes, and in Cramer’s words, “What Jay Powell said was extremely bullish.” Explaining in better detail, Cramer says, “When the Fed gets out of the way, you have a real window and you’ve got to jump through it... When a recession comes, the Fed has the good sense to stop raising rates. And that pause means you’ve got to buy stocks... I think that window has finally arrived, and you don’t want to close it on yourself.” -----------------------------------------------------------------------
“In the latest sell-off, JPM estimates 3-4x higher buyback executions than trend, which implies the corporate put remains active,” JPMorgan’s Marko Kolanovic writes earlier this year. The analyst points out that in Q1, S&P 500 companies bought back 45% more of their shares compared to the year-ago period. And since corporations continue to gush cash flow, more buybacks could be on the way. Most recently, Kolanovic notes how even the Fed might be more dovish than expected. “In response to economic weakness and declining inflation expectations, rate markets are already sensing a Fed policy reversal by pricing in an earlier (January 2023 vs. August 2023 in mid-June) and lower Fed funds rate peak (3.3% currently vs. a 4% peak in mid-June),” the analyst writes on Wednesday. “We thus remain cautiously optimistic and continue to combine a sizeable equity overweight in our model portfolio with a credit underweight as a hedge.”
Believing they heard a dovish tilt from Jerome Powell, traders pushed the S&P 500 up nearly 4% over two days -- and kept on buying Friday. Welcome as it was by bulls, the spike raises the question of when the rebound itself starts to work against the goal of draining bloat from the economy. It’s an issue investors must weigh in calculating the recovery’s staying power. A dynamic in which surging stocks complicate the goal of subduing inflation is one reason giant rallies are rare in times of tightening. While the Fed may be ambivalent about equities in general, the role of markets in mediating a real-world economic lever -- financial conditions -- means they are never completely out of mind. Right now, those conditions are loosening in proportion to the S&P 500’s gains. Could that be a concern for Powell? The Fed chief said Wednesday that policy makers will be monitoring whether financial conditions -- a cross-asset measure of market stress -- are “appropriately tight.” But in the days since the central bank’s second straight 75 basis point hike, the measure is now at a level looser than before the first rate hike in March. “They don’t want easier financial conditions, because they want lower demand,” Bespoke Investment Group global macro strategist George Pearkes said. “Basically, markets are assuming we’ve hit peak hawkishness and we’ll be easing sooner than expected. I’m skeptical the Fed is going to endorse that.” The S&P 500 soared 4.3% for the week and 9.1% in July, the best monthly advance since November 2020. Its gains snowballed after Powell raised rates three-quarters of a percentage point and suggested the pace of hikes might slow later this year. The nearly 4% jump on Wednesday and Thursday alone was the biggest two-day gain on record following Fed tightening. The risk-on impulse spread to corporate bonds, with both investment-grade and high-yield spreads narrowing from peaks earlier in the month as traders trimmed wagers on an ultra-aggressive Fed. Treasury yields dropped across the curve as well, with 10-year Treasury yields dropping to 2.65% after reaching 3.5% in June. Taken together, the equity and bond rallies helped loosen US financial conditions, which clocked in at -0.46 compared to a -0.79 reading in March, according to a Bloomberg measure. The easing of that key metric could be setting up for disappointment traders who have gone all-in on the idea of a friendlier Fed, Nuveen’s Brian Nick. “If the Fed’s goal by raising interest rates is to slow the economy by tightening financial conditions, then that hasn’t happened since they started to get more serious about rate hikes,” said Nick, chief investment strategist at Nuveen. “I’m afraid we’re in for another instance of what’s become very familiar, which is the Fed has to bring the party to a halt at its next meeting or before that.” That fear isn’t reflected in market pricing. Swaps show that traders expect the fed funds rate to peak around 3.3% before the end of 2022, less than a percentage point above its current level. At one point in recent months, that level was approaching 4%. While the Fed would likely prefer to see continued tightening, conditions have still compressed “significantly” in recent months, said iCapital’s Anastasia Amoroso. “Financial conditions have tightened a whole lot since the beginning of the year,” Amoroso, chief investment strategist at iCapital, said in an interview at Bloomberg’s New York headquarters. “The fact that credit spreads have been tighter, the fact that equity prices have been lower, the fact that rates across the curve have been much higher, this is going to exert still downward pressure on the economy in the coming months.” - Bloomberg
“The Fed is trying to get Goldilocks,” Patterson told host David Westin. “I think it’s going to be almost impossible for the Fed to get everything it wants. The porridge is going to be too hot or too cold.” The S&P 500 soared 4.3% for the week and 9.1% in July, following the worst six-month start to a year since 1970. Stock gains snowballed this week after Fed Chairman Jerome Powell suggested the pace of rate hikes may slow later this year. The central bank has boosted its target rate by a cumulative 2.25 percentage points so far in 2022, including 75 basis points this week. Bonds also rallied, with 10-year Treasury rates ending the week at 2.65%, down from a 3.47% high in June. That conflicts with the bearish outlook by Bridgewater, the world’s biggest hedge fund firm, which anticipates falling bond prices as the Fed downsizes its balance sheet and floods the market while simultaneously being forced to make more hikes to cool inflation, Patterson said. “We think within six to nine months, we’re going to be looking at US GDP that’s negative 2, negative 3%,” she said.
It's not gone well for me so far folks in my solar play. I'm going to adjust my cost basis today and Double Down on this loser.-! Northland starts 'differentiated' Sunworks at Outperform 08:01 SUNW As previously reported, Northland analyst Donovan Schafer initiated coverage of Sunworks with an Outperform rating and $4.50 price target. Sunworks is the only publicly traded solar company with a primary focus on controlling the procurement, logistics, and installation processes as key competitive advantages as far as he can tell, Schafer tells investors. Given this "differentiated" installation-focused business model for residential solar-plus-storage, he sees "a compelling investment at current levels," Schafer said. SUNW-$1.79 SUNW- $2.38 clawing back!
I wrote this a while back-- Solar is the topic of the day. It is such a tough sector. CSIQ was always my play back in the day.But there is Jinko JKS and many others<-- I've been burned before with false break outs but part of this Russian story is no one wants Russian oil anymore. And it really is going to speed up large scale solar projects... We probably want exposure in Germany and France & US... and then it gets complicated about who has a commodity part of solar and who has panels, who has the chips> and then it gets more complicated who had the lowest cost,,, it's a tough a sector. If you want to make a lot of money- 100% and you have some stomach for pain,you may want to take a look at a stock of mine that I have gotten beaten up in good. I am still a holder - waiting for price of steel to come down because that's a huge imput cost for these guys... But at $11 they are giving this stock away. Array makes metal couplings that rotate so solar panels can move and always catch the suns most direct angle<-- increases effeciency. Array Technologies, Inc. (ARRY) NasdaqGM - NasdaqGM Real Time Price. 11.36+0.12(+1.11%) As of 09:52AM Update- $16.85
Robinhood alert: Watch this one today. $AMTX $1.88 I originally gave this idea to the Children at $1.88 // Then again at $4.- The Children gained 400% and then another 100%.... That's quite a return for a stock that Van was not that sure about. I was accused of " pimping " loser stocks.... 500% Return is Pimping... I guess that's why they wear those felt hats. The stock roared to $8 where to give Van credit he got us out. Now we are back to $7.50 area..... It's a good watch here if it breaks above $8 the road to $14 has begun. If it gets there-- $1.88---------> $14.00 That's going to be a MURDER IN THE MARKET.